Letrozole Teva

Letrozole, the active ingredient in Letrozole Teva, is an aromatase inhibitor presented as an oral tablet for oral use. It is employed in the hormonal management of estrogen‑dependent breast cancer in postmenopausal women, reducing peripheral estrogen synthesis and is prescribed as part of adjuvant or metastatic therapy protocols.

GNH USA supplies Letrozole Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide with a focus on quality assurance and regulatory compliance across EU and global markets.

Letrozole is used in hormone‑dependent breast cancer pathways to lower estrogen levels. - Postmenopausal hormone receptor‑positive breast cancer: reduces tumor growth and recurrence risk. - Advanced or metastatic breast cancer in postmenopausal women: slows disease progression. - Adjuvant therapy after surgery for estrogen‑dependent breast cancer: helps prevent disease return.

Letrozole may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hot flashes: sudden feeling of warmth and sweating. - Joint and muscle pain: arthralgia or myalgia. - Fatigue: persistent tiredness. - Nausea: upset stomach and urge to vomit.

Serious or Rare Side Effects: - Severe osteoporosis: increased risk of bone fractures. - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Liver function abnormalities: elevated transaminases or hepatitis.

When prescribing Letrozole, clinicians should consider several safety measures. - Monitor bone mineral density: assess risk of osteoporosis regularly. - Assess cardiovascular status: watch for signs of thrombosis or hypertension. - Check liver function tests: evaluate hepatic enzymes before and during therapy. - Avoid use in pregnancy: teratogenic potential unknown; contraindicated. - Inform patients about hot flashes and joint pain: provide supportive measures. - Store at ambient temperature below 25°C: keep in original packaging, protect from moisture and light.

Letrozole can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Concurrent use of estrogen replacement therapy: negates drug effect. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly reduce plasma levels.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin): may increase bleeding risk; monitor INR. - Selective serotonin reuptake inhibitors (SSRIs): may exacerbate nausea. - Tamoxifen: antagonistic effect on estrogen pathways; avoid combined use.